High risk and intermediate-2 risk myelofibrosis

Treatment Phase: Continuing treatment

Clinical criteria:

  • Patient must have previously received PBS-subsidised treatment with this drug for this condition,

AND

  • The treatment must be the sole PBS-subsidised JAK inhibitor therapy for this condition.

Treatment criteria:

  • Must be treated by a medical practitioner; OR

  • Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a medical practitioner, (ii) the prescription continues existing therapy with this medicine.

Note

Risk of myelofibrosis is defined in accordance with the Myelofibrosis International Prognostic Scoring System (IPSS) or the Dynamic International Prognostic Scoring System (DIPSS) or the Age-Adjusted DIPSS.

Note

No increase in the maximum quantity or number of units may be authorised.

Note

No increase in the maximum number of repeats may be authorised.

Note

Special Pricing Arrangements apply.

Intermediate-1 risk myelofibrosis

Treatment Phase: Continuing treatment

Clinical criteria:

  • Patient must have previously received PBS-subsidised treatment with this drug for this condition,

AND

  • The treatment must be the sole PBS-subsidised JAK inhibitor therapy for this condition.

Treatment criteria:

  • Must be treated by a medical practitioner; OR

  • Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a medical practitioner, (ii) the prescription continues existing therapy with this medicine.

Note

Risk of myelofibrosis is defined in accordance with the Myelofibrosis International Prognostic Scoring System (IPSS) or the Dynamic International Prognostic Scoring System (DIPSS) or the Age-Adjusted DIPSS.

Note

No increase in the maximum quantity or number of units may be authorised.

Note

No increase in the maximum number of repeats may be authorised.

Note

Special Pricing Arrangements apply.